NCT04642378View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of iNCDSS in Type 2 Diabetes Mellitus Patients

NACompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

September 8, 2022

Study Completion Date

September 8, 2022

Conditions
Type 2 Diabetes
Interventions
DRUG

iNCDSS based insulin regime

Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).

DRUG

routine insulin treatment regime

Patients of this group will receive the insulin regime recommended by professional endocrinologists.

Trial Locations (1)

200032

180 Fenglin Road, Shanghai

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

XuHui Central Hospital of Shanghai, Shanghai, China

UNKNOWN

lead

Shanghai Zhongshan Hospital

OTHER

NCT04642378 - Study to Assess the Efficacy and Safety of iNCDSS in Type 2 Diabetes Mellitus Patients | Biotech Hunter | Biotech Hunter